Clinical Trial Update: EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating EXL01 in combination with Nivolumab for advanced non-small cell lung cancer refractory to immunotherapy; recruitment is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EXL01
• nivolumab (nivolumab)

Snippet

Sponsor: University Hospital, Lille | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING